Moderna and BioNTech, the two companies that rose to prominence during the COVID-19 pandemic, are taking different financial paths as they attempt to move beyond their reliance on vaccine revenue.
While both firms saw product sales peak near $18 billion—BioNTech in 2021 and Moderna in 2022—the companies are now shifting their focus toward oncology to sustain long-term growth.
Moderna has shown recent signs of a financial turnaround. In the third quarter of 2026, the company reported revenue of $1.3 billion, a 29% increase, and a net income of $162 million. This represents a significant shift from the losses recorded a year prior. Management has responded to this momentum by raising its 2026 revenue growth outlook to a range of 15% to 25%, up from a previous forecast of 10%.
The company currently has five approved products, including a flu vaccine that received U.S. approval this year.
BioNTech remains focused on its extensive research portfolio, maintaining more than 25 clinical trials in phase 2 and phase 3 for cancer treatments. The company reported a net loss of nearly $1.3 billion for the 2025 fiscal year, a result of the substantial capital redirected toward its oncology pipeline. This performance resulted in a net margin of approximately -39.6%.

Despite the losses, BioNTech maintains a strong liquidity position. As of the end of September 2026, the company held approximately €16.2 billion in cash and investments, which provides flexibility to fund its clinical development without relying on external financing.
Both companies face mounting external challenges. BioNTech is also evaluating its lead candidate, pumitamig, a bispecific antibody developed with Bristol Myers Squibb. Though the candidate met its primary endpoint, its impact may be “limited,” the companies said.
BioNTech faces a major transition as it prepares for the departure of CEO Uğur Şahin and chief medical officer Özlem Türeci at the end of this year. A new CEO is scheduled to take over by Feb. 1, 2027, marking a period of major change for the firm.

Moderna is looking toward several catalysts in 2027, including potential regulatory discussions regarding its personalized cancer vaccine candidate, intismeran. The company also expects to gain market share in Europe as a competitor’s COVID-19 vaccine contract expires.
Moderna’s lead candidate, intismeran, is currently involved in four phase 3 trials. In a phase 3 melanoma trial, the treatment combined with Merck’s Keytruda reduced the risk of recurrence or death by 42% compared to Keytruda alone.
Why is BioNTech’s leadership changing? The company is undergoing a planned leadership overhaul, with the current CEO and chief medical officer stepping down at the end of 2026. A successor is expected to be in place by Feb. 1, 2027, to oversee the company’s next phase of development.
Moderna was founded in 2010 and focuses on RNA therapeutics, with its name derived from the terms “modified”, “RNA”, and “modern.” The company achieved a milestone in 2018 by launching the largest initial public offering of a biotechnology company in history, raising $621 million. By May 2026, the organization was ranked first on Time’s list of the World’s Most Impactful Companies.
It is unclear how BioNTech’s new leadership will influence its strategy for commercializing its pipeline, and whether Moderna can successfully maintain its recent revenue growth as it awaits regulatory decisions for its cancer therapy.